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ImagingBackground/objectives: Binding sites are the principal cause of failed lead removal and complications, and are not
directly visualized byﬂuoroscopy.We aimed to assess binding sites between permanent cardiac pacing leads and
cardiovascular structures using CartoSound™ three-dimensional (3D) imaging technology (Biosense Webster
Inc., Diamond Bar, CA) during transvenous lead extraction, and compared outcomes to standard approach.
Methods:We recruited 291 patients undergoing percutaneous lead extraction, and 3D CartoSound anatomical
mapping of the superior vena cava, right atrium (RA), coronary sinus, right ventricle (RV), pacing leads, and
binding sites before, during, and after lead removal was randomly performed in 46 of them (38 men; mean
age 73.7 ± 10.5 years; 1.96 leads/patient; mean time-from-implant of 62.7 ± 51.8 months) using a 10-Fr 3D
SoundStar™ catheter and integrated into the Carto® mapping system.
Results: CartoSound was able to detect more intracardiac binding sites compared to ﬂuoroscopy (RA 17.4% vs.
4.3%, p = 0.04; RV 43.5% vs. 21.7%, p = 0.04), but was unable to assess the subclavian/innominate veins.
Binding sites volume correlated positively with time-from-implant (r = 0.38, p b 0.05), and powered-sheath
use (r= 0.39, p b 0.05), and negatively with procedural success (r=−0.37, p b 0.05). When compared to stan-
dard approach, CartoSound use was characterized by a signiﬁcantly lower mean procedure time (p = 0.0001),
major complications (p = 0.03), and greater procedure success rates (p = 0.03).
Conclusions: Real-time 3D binding sites assessment is feasible and improves transvenous lead extraction outcomes.
Its role as a complementary information requires extensive validation, andmight be beneﬁcial for a tailored strategy.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiac permanent pacing lead extraction procedures are increas-
ingly performed [1–3], but only when beneﬁts of removal outweigh
signiﬁcant procedural risks [4]. Binding sites between leads and the
cardiovascular structures are the principal cause of partial or failedsional; ECG, electrocardiogram;
e; RA, right atrium; RV, right
chocardiogram.
tion, Cardiology Department,
le del Policlinico 155, 00161
).
eliability and freedom from bias
. This is an open access article underremoval and complications. Determining the degree of ﬁbrosis could
help stratify perioperative challenges. Transvenous manipulation and
extracting tools may disrupt scarred binding sites along the lead and
tear it off the cardiovascular wall under X-ray monitoring. However,
ﬂuoroscopic imaging is unable to visualize binding sites other than
by absent lead movement during manual traction throughout the
procedure and to detect in a timely manner major complications [5].
There is currently a lack of routinely used imaging modality to stratify
challenging procedures.
Recently, turbulentﬂow in the superior vena cava (SVC) using color-
Doppler echocardiography demonstrated to be a noninvasive method
to identify lead ﬁbrosis and complex lead extraction procedures [6].
Two-dimensional (2D) intracardiac echocardiography (ICE) proved
to be an effective alternative real-time modality to assist lead removal
and improve procedure efﬁcacy and safety by its ability to visualize
ﬁbrotic binding sites [7]. Three-dimensional (3D) CartoSound™Module
integrates real-time 2D ICE imaging into the Carto® electroanatomicthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient clinical and lead characteristics.
CartoSound Fluoroscopy p
Patients 46 245 NA
Pacing leads 90 409 NA
Leads per patient 1.96 1.67 0.009
Mean age, y-o ± SD 73.7 ± 10.5 72.4 ± 11.9 0.4
Men, % 82.6 (38/46) 68.7 (169/245) 0.07
Mean time-from-implant, months ± SD 62.7 ± 51.8 52.3 ± 106.1 0.5
Lead location, %
• right atrium 44.4 (40/90) 42.1 (172/409) 0.7
• right ventricle 48.9 (44/90) 50.9 (208/409) 0.8
• coronary sinus 6.7 (6/90) 7.1 (29/409) 1
High voltage coil, % 13.3 (12/90) 16.1 (66/409) 0.6
Lead ﬁxation, %
• active 42.2 (38/90) 37.9 (155/409) 0.4
• passive 57.8 (52/90) 62.1 (254/409) 0.4
NA: not applicable.
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CA), enhancing visualization and conﬁdence during electrophysiology
procedures for cardiac arrhythmias [8].
We hypothesized that a 3D imaging of binding sites, and knowing
their volume and relationships to pacing leads and cardiovascular
structures during lead extraction would help procedural outcomes.
We sought to assess the feasibility and safety of this technique and
compared it to standard approach.
2. Methods
2.1. Study population
We recruited a total of 291 patients undergoing percutaneous
lead extraction at our Institution between September 2011 and
May 2015. Forty-six of them were blindly and randomly (1:6)
assigned to undergo 3D CartoSound anatomical mapping during the
procedure. Patients were referred for pacemaker and implantable
cardioverter-deﬁbrillator lead removal class IB indication (all cardiac
device infections) and pre-operatively examined according to current
guidelines [9]. The research protocol conforms to the ethical guidelines
of the 1975Declaration ofHelsinki andwas approvedby the Institutional
Review Board, and written informed consent was obtained from all
patients before removal.
2.2. Pre-procedural examination and preparation
Cardiac implantable electronic device removal was performed in the
cardiac electrophysiology laboratory under local anesthesia or sedation.Fig. 1.Number of binding sites identiﬁed by ﬂuoroscopy (X-ray) and CartoSound imaging at var
atrium; RV = right ventricle; Subclavian = subclavian vein; SVC = superior vena cava.Cardiothoracic surgery stand-by was available. Surface 12-lead
electrocardiogram (ECG) was monitored, cutaneous deﬁbrillation
pads were applied, transvenous temporary pacing was placed in
the right ventricular (RV) apex (RVA) through a femoral vein when
required, and arterial blood pressure with pulse oximetry monitoring
was available during the procedure.
2.3. CartoSound registration
The 3D CartoSound Module and 10-Fr 3D SoundStar™ catheter
integrate real-time 2D ICE imaging into the Carto system environment.
The latter is a non-ﬂuoroscopic cardiac mapping system that ensures
precise real-time tracking of catheter tip location by means of a tipped
miniature magnetic ﬁeld sensor, electrode patches attached to the
body surfacewithmagnetic sensors, and an external ultra-lowmagnetic
ﬁeld emitter under the catheterization table. A processing unit receives
data from the sensors on the amplitude, frequency and phase of the
magnetic ﬁelds emitted allowing determination of the precise location
and orientation of the catheter tip, as previously described [8]. The
SoundStar probe tip 3D location and direction is established by the in-
corporated tipped miniature magnetic ﬁeld sensor and an ultrasound
linear phased-array AcuNav™ ICE catheter platform (multifrequency
5–10 MHz, 64-element, pulsed and colorDoppler ultrasound, tissue
penetration ≤10 cm, 4-way head articulation). Real-time 90° cross-
sectional images (30 frames/s) were recorded by a dedicated console
(ACUSON Cypress™, Siemens AG, Malvern, PA). Three-second seg-
ments of 2D ultrasound images were acquired during ECG gating
and displayed within the Carto coordinate workspace. Complete
integrated 3D CartoSound anatomical maps were created immediately
before, during, and shortly after lead removal.
The SoundStar catheter was gently advanced from the inferior vena
cava via a femoral vein under ﬂuoroscopic monitoring. A “standard
view” was obtained with the probe tip in the mid-right atrium (RA)
facing anteriorly. In each patient, several 2D-slice sections of the SVC,
RA, RV, coronary sinus, tricuspid valve, pacing leads, and binding sites
were acquired from catheter manipulation to create the 3D CartoSound
anatomical maps. Each 2D imagewas optimized by adjusting tissue res-
olution and penetration, and displayed on the system's “Ultrasound
Viewer,” from which the endocardial surface contour was identiﬁed
and traced automatically or overwritten by hand if necessary on
the basis of echo-intensities at the blood-tissue interface. High echo-
intense areas at blood-tissue interface were assigned as binding site
areas by the operator. Each surface contour was stored to delineate
planar-shaped series of anatomic mapping points. By repeating this
process, a family of chamber contourswere interpolated into a complete
volume rendering, that were displayed on the Map Viewer within the
Carto x, y, and z coordinates, that accurately showed a color-codedious cardiovascular locations. Between leads= betweenmultiple pacing leads; RA= right
Fig. 3. Correlation between binding sites volume and time from implant of pacing leads.
The scatter diagram shows the relation between the binding sites volume at the time
of CartoSound evaluation during lead extraction and the time from implant of the leads.
As shown, the volume of binding sites quantiﬁed by CartoSound imaging is associated
with the time from lead implantation.
Fig. 2. CartoSound 3D anatomical mapping of the SVC, RA, and RV showed by the
map viewer (left and mid panels) from real-time ICE images showed by the ultrasound
viewer (right panels). Multiple endocardial contours (mesh) of the SVC, RA, RV borders
(in green), catheters (multiple red lines), and binding sites (in blue, white arrows) are
manually drawn. Panel A: PA view of binding sites located in the SVC; Panel B: RAO
view of binding sites located at the SVC-RA junction/RAA roof; Panel C: RAO view
of binding sites located at the RVA. ICE = intracardiac echocardiography; PA: posterior–
anterior; RAA = right atrial appendage; RAO: right anterior oblique; RVA = right
ventricular apex; RV = right ventricle; SVC = superior vena cava.
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binding sites colored in blue, and manually delimitated for volume cal-
culation. Shortly after lead removal, possible sites of pericardial effusion,
and tricuspid valve morphology and function were assessed using the
color-Doppler function. Possible pulmonary embolism was assessed
using pulse oximetry and Computed Tomography scan.
CartoSound evaluation time was deﬁned as the time since 3D map
creation to the 3D assessment of binding sites.
2.4. Lead extraction procedure
Leads were removed mainly via the implant vein, none were re-
moved using the jugular approach [5]. Leads were freed from adhesionsdown to the insertion site, securedwith ties of silk suture around the in-
sulation, and visually examined by ﬂuoroscopy in their intravascular
segment. Fluoroscopic identiﬁcation of intracardiac binding sites was
deﬁned as absent lead movement during manual traction throughout
the procedure. Transvenous lead extraction was performed manually
with or without the assistance of traction devices and other devices
used to disrupt ﬁbrous tissue from the lead [10]. Gentle manual traction
of the lead was ﬁrst attempted. Subsequently, locking stylets were
introduced into the central lumen of the inner coil and anchored in its
most distal part as far as possible (Lead Locking Device 1, 2, and EZ
LLD™, Spectranetics®, Colorado Springs, CO) to uniformly increase
lead body tensile strength and aid traction near the tip. Non-powered
and powered telescoping dissecting sheaths were also used to dissect
binding sites [11]. Mechanical sheaths (7-Fr or 11-Fr polypropylene or
Teﬂon, Byrd, Cook®Medical Inc, Bloomington, IN) allowed blunt dissec-
tion through adhesions to free the lead body from the vascular wall.
Laser sheaths used an energy source to break down adhesions (12-Fr,
14-Fr or 16-Fr Laser Sheath SLS® II, Spectranetics Corp). At its distal
tip, the layer of spirally wrapped optical ﬁbers produce a single ring of
pulsed excimer laser light, and was activated as ﬁbrotic binding sites
were encountered. Maneuvers and safety precautions were adopted as
previously described [5,11,12]. Femoral extraction tools and snares
were adopted in case the leadwas no longer accessible from the original
venous entry site or for lead fractures or fragments. In the CartoSound
group, the 3D imaging results of the binding sites were used to modify
the lead extraction technique. Laser sheaths were used when at least
one binding site volume was above 1.0 cm3. Procedural outcomes and
complications were deﬁned according to recommendations [4,9].
Extraction time was deﬁned as the time since the start of traction or
dilation to lead removal. Procedure time was deﬁned as the time since
local anesthesia to lead removal including 3D CartoSound assessment.2.5. Statistical analysis
Continuous variables were expressed asmean± standard deviation.
Categorical data were expressed as percentages. Possible relationships
between continuous variables were determined using a Pearson
correlation coefﬁcient whereas categorical variables were correlated
usingWilcoxon rank-sum test (SPSS software v13, SPSS Inc., Chicago, IL).
Student paired t test was used to evaluate the clinical signiﬁcancewhere
p values b0.05 were considered statistically signiﬁcant.
Fig. 5. Correlation between lead extraction success and binding sites volume. The scatter
diagram shows the relation between procedural lead extraction success and the binding
sites volume at the time of CartoSound evaluation indicating a negative correlation.
As shown, the procedural success is inversely associated with the volume of binding
sites quantiﬁed by CartoSound imaging.
Fig. 4. Correlation between powered-sheath use and binding sites volume. The scatter
diagram shows the relation between powered-sheath use during transvenous lead
extraction and the binding sites volume at the time of CartoSound evaluation. As shown,
the use of powered-sheaths is associated with the volume of binding sites quantiﬁed by
CartoSound imaging.
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3.1. Patient clinical and lead characteristics
Data are summarized in Table 1. Over a cohort of 291 patients,
245 underwent lead extraction using a standard approach, and
46 (38 men, mean age 73.7 ± 10.5 years) underwent the procedure
using CartoSound 3D binding sites volume assessment. Leads had
been implanted for a mean period of 62.7 ± 51.8 months (median
60months, range 7–180months). A total of 90 leads (1.96 leads/patient)
were explanted during 3D binding sites volume evaluation.
3.2. Procedural lead extraction and CartoSound characteristics
The number of 2D CartoSound slices acquired for anatomical map
reconstruction were 5.2 ± 1.8 for the SVC, 7.9 ± 2.1 for the RA, and
9.9 ± 2.3 for the RV. CartoSound 3D maps were completed in all
patients, providing qualitative, quantitative, and localization informa-
tion on the binding sites of leads to anatomical structures.
3.3. Pacing lead assessment
Pacing leads were visualized in all patients as circular (transversal
view) or linear (longitudinal view) depending on the probe position
and lead direction, and color-coded in red. The system was also able
to easily distinguish between free-ﬂoating leads or leads adherent
to the venous wall or to the endocardium. Lead course was followed
clearly to the myocardial insertion site of its tip.Table 2
Procedural outcomes.
CartoSound Fluoroscopy p
In-hospital major complications, % 0 (0/46) 2 (5/245) 0.03
Success, % 93.5 (43/46) 80.4 (197/245) 0.03
Procedure time (min), mean ± SD 30.1 ± 23.2 90 ± 34 0.0001
X-ray exposure time (min), mean ± SD 15.6 ± 19.3 24.2 ± 10 0.0001
2D ICE imaging acquisition time (s),
mean ± SD
17.6 ± 11.2 NA NA
3D CartoSound imaging evaluation
time (min), mean ± SD
4.9 ± 2.3 NA NA
NA: not applicable.3.4. 3D binding sites assessment
Binding sites location assessment using CartoSound and ﬂuoroscopy
are summarized in Fig. 1.
Binding sites were visualized as echo-intense structures along
the lead, often highlighted by a linear ultrasound shadow, and
color-coded in blue. Scar tissue was usually present at the site of lead
binding site to the venous wall or to the endocardium. CartoSound
was able to detect binding sites in the SVC in 56.5% (Fig. 2, Panel A),
RA in 17.4% (Fig. 2, Panel B), RV in 43.5% (Fig. 2, Panel C), and between
leads in 8.7% of the cases. The subclavian/innominate venous regionwas
not easily reachable with the currently available CartoSound probe and
registration was not performed.
On the other hand, ﬂuoroscopy assessment identiﬁed lead binding
sites to the cardiovascular system by a reduced movement on X-ray
during the cardiac cycle at the venous subclavian entry site in 69.6%
(p = 0.0001), SVC in 39.1% (p = 0.1), RA in 4.3% (p = 0.04), RV in
21.7% (p = 0.04), and between leads in 8.7% (p = 1 vs. CartoSound,
respectively) of the cases (Fig. 1).
The mean volume of binding sites was 2.0 ± 1.6 cm3. Based on
CartoSound ﬁndings, 3D binding sites volume correlated positively
only with the time from implant as a clinical variable (r = 0.38,
p b 0.05, Fig. 3).
3.5. Procedural lead extraction technical characteristics
Powered-sheath use correlated positively with 3D binding sites
volume identiﬁed by CartoSound imaging (r = 0.39, p b 0.05, Fig. 4),
and with the time from lead implantation (r = 0.34, p b 0.05).
3.6. Procedural outcomes
Data are summarized in Table 2. Procedural outcomes using 3D
binding sites volume assessment are listed. Mean procedure time of
30.1 ± 23.2 min, and X-ray exposure time of 15.6 ± 19.3 min were
all signiﬁcantly lower compared to standard approach (90 ± 34 min,
p = 0.0001; 24.2 ± 10 min, p = 0.0001, respectively). Mean 3D
CartoSound evaluation timewas 4.9± 2.3min, with amean time to ob-
tain a 2D ICE image of 17.6 ± 11.2 s. Procedural success rate improved
using 3D CartoSound imaging compared to standard approach (93.5%
vs. 80.4%, p = 0.03, respectively), and correlated negatively with
the volume of binding sites identiﬁed (r = −0.37, p b0.05, Fig. 5).
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standard approach (2%, p = 0.03, 3 deaths, 2 cardiovascular avulsions
requiring drainage).
4. Discussion
To our knowledge, this is the ﬁrst description of a 3D binding
sites volume assessment using a cardiacmapping system during chron-
ically implanted cardiac pacing lead extraction. The advancement of
extracting tools under X-ray aims to disrupt scar tissue along the lead
and tear it off the cardiovascular wall and is hampered by binding
sites. Fluoroscopy is limited by the inability to: distinguish venous and
myocardial walls and conﬁrm that the sheath follows an intravascular
course; detect dangerous venous and cardiacwall displacements during
sheath advancement such as vessel torsion or myocardial invagination;
visualize binding sites; promptly detect potential life-threatening
complications [5]. With expanding indications for cardiac device im-
plantation, dealing with the challenges of chronically implanted leads
removal has also increased. Since there may be a correlation between
the degree of ﬁbrosis and procedure complexity, assessing binding
sites could help stratify perioperative risk. There is currently a lack of
routinely used imaging modality to stratify challenging procedures.
Ultrasound imaging modalities have been evaluated to assist lead ex-
traction. Turbulent ﬂow in the SVC using color-Doppler echocardiogra-
phy predicts lead ﬁbrosis and complex lead extraction procedures [6].
Transesophageal echocardiogram (TEE) is logistically difﬁcult as it
requires the presence of an anaesthesiologist and an Echo operator
[13]. A mechanical rotational 2D ICE 360° probe (Ultra ICE™, Boston
Scientiﬁc Corp, Boston,MA)was successfully used to guide lead removal
[6]. Two-D ICE is commonly used as an alternative to TEE for a number
of cardiac interventional procedures [14], andmonitor acute procedure-
related complications. It requires additional 10-Fr sheath femoral
venous access, and increased costs, offset by the use of local anesthesia,
and shows several advantages in terms of ﬂuoroscopy and procedure
time, patient's discomfort, and hospital stay [15,16]. However,
2D ultrasound suffers from the known operator-dependent limitations,
and from being a technology with a limited ﬁeld-of-view, therefore not
providing information on leads and binding sites in the 3D space. The
introduction of non-ﬂuoroscopic electro-anatomical mapping systems
improved cardiac electrophysiology procedures efﬁcacy and safety.
Real-time 3D ultrasound-derived CartoSound geometries [8,17,18]
beneﬁt from the integration of 2D phased-array ultrasound images
into the 3D electromagnetic database of a mapping system to improve
spatial resolution, and real-time tracking. We used this 3D technology
for the ﬁrst time to carefully look for attachments to pacing leads and
to different anatomical structures, and assess their volume.
Our ﬁndings suggest that CartoSound 3D anatomical mapping is
feasible during chronically implanted pacing lead extraction. This
technology better identiﬁes intracardiac binding sites compared to ﬂuo-
roscopy, and was able to assess their volume, that correlates positively
with time from implant and powered-sheath use, and negatively with
procedural success. We also conﬁrmed a positive correlation between
the use of powered-sheaths and time from implant, as previously
reported [19]. Since binding sites are not directly detectable by
ﬂuoroscopy other than absent lead movement during manual traction
throughout the procedure, information provided by 3D anatomical
mapping, in addition to clinical data [20], might be helpful in stratifying
procedural risks and planning themost appropriate procedural approach.
In our limited experience, 3D binding sites volume assessment im-
proved procedural outcomes compared to standard approach, in terms
of lower procedure time, X-ray exposure time, major complications
and greater procedure success despite the lead/patient ratio was signif-
icantly greater in these subjects. CartoSound assessment did not affect
procedure time and X-ray exposure time that were similar to prior
reports [12]. We suspect that this imaging technique could potentially
decrease overall surgery and X-ray time with experience, but furtherstudies are warranted to prove these beneﬁts. Cardiac pacing lead
extraction is considered a high-risk procedure. Risk reduction depends
primarily on avoidance and early identiﬁcation of potentially life-
threatening cardiovascular complications, such as severe local bleeding,
cardiac dysfunction, and embolization. Technological efforts to
overcome these limitations are warranted.4.1. Study limitations
This is a single-center experience. Multi-center studies are required
to better deﬁne the role of 3D binding sites assessment during lead
extraction. Possible correlations, such as between binding sites volume
and patient or lead characteristics, were beyond the scope of our
study and remain to be done. In addition, we did not compare this
methodwith other ultrasound imaging techniques, nor didwe compare
it for adhesions detection with magnetic resonance (MR), since it was
beyond the scope of this study, and the explanted devices were
not MR-conditional. Further studies are needed to compare this new
technique with other technologies, especially with the recently
implanted MR-conditional devices.
Thismethod is potentially limited by its operator-dependency as the
high echo-intense areas are manually assigned, and by the inability to
screen the subclavian/innominate venous region, common binding
sites and difﬁcult areas to cross the transvenous sheaths. In fact, as op-
posed to the intracardiac locations, ICE imaging of the lead-scar-tissue
interface at venous sites is often confounding and difﬁcult to accurately
characterize and trace bindings sites because: 1) the layer ofﬁbrous scar
binding the lead to the vascular wall is usually very thin, 2) the images
quality immediately adjacent to the leads is very poor due to the
metal-induced artifact from lead conductors and high-voltage coils,
especially in the opposite side from the ICE transducer.
Several other technologies, such as 3D ICE and 3D TEE [21,22],
aswell as 4D ICE [23] are under evaluation andmay provide new clinical
information not possible with current 2D imaging catheters. Because of
the imaging challenges at the lead-scar-tissue interface, technology
improvements might allow the assessment of these venous regions
so important for frequent occlusion and difﬁculty of crossing with
extraction sheaths. Moreover, future extracting tools might have ring
electrodes on them to be visualized and tracked on the 3Dmapping sys-
tem and help direct the manipulation over the identiﬁed binding sites.5. Conclusions
Real-time 3D binding sites volume assessment using CartoSound
anatomical mapping is feasible and may provide incremental informa-
tion during chronically implanted pacing lead extraction. Its role as a
complementary imaging tool to increase challenging procedures out-
comes requires extensive validation. Knowing more about binding
sites volume andmorphology might be beneﬁcial for a tailored strategy
and could help stratify perioperative risk. Large multi-center
randomized controlled trials are required to allow a change in
routine clinical practice.Acknowledgments
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